Home > Press Release > Latest News
|ESOMEZOL launched in the United States18, Dec. 2013|
ESOMEZOL launched in the United States
■ Amneal starts shipping to wholesalers on December 18th
Hanmi Pharmaceutical (Gwan Sun Lee, President and CEO) announced that 'Esomezol’, Hanmi's drug for the treatment of gastroesophageal reflux disease (GERD) is launched in the US market under the name of 'Esomeprazole Strontium'.
According to Amneal Pharmaceuticals, the US partner of Hanmi, the first shipping to 3 major U.S. pharmaceutical wholesalers would be made on December 18th, 2013.
Esomeprazole Strontium contains the same active moiety (esomeprazole) in a different salt form as found in the branded proton-pump inhibitor Nexium®(esomeprazole magnesium) and is a new option for adult patients for the short term treatment of gastroesophageal reflux disease (GERD).
On August 6, 2013, Esomeprazole Strontium became the first drug developed by a Korean company and received the market authorization of U.S. FDA.
Gwan Sun Lee, President and CEO of Hanmi, stated, "We are planning to gain as much market share as possible before the expiration of Nexium patent and the entry of more competitors, through strategic partnership with Amneal pharmaceuticals."
|HANMI ANNOUNCES LAUNCH OF ESOMEPRAZOLE S..|
|Sanofi-Hanmi launches Robelito, the firs..|
45 Bangi-dong. Songpa. Seoul 138-724 Korea Tel 82. 2. 410. 9114
Copyright (c) 2004 by Hanmi Pharm Co Ltd. All rights reserved